Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IBSE: GENIL)
Health Care · Pharmaceuticals · TR
TL12.15
+11.16% today · -11.5% 1Y
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IBSE: GENIL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.14B and employs 682 people.
Over the last twelve months the share price has lost 11.5%, trading between 7.12 and 14.93.
Tweenvest scores Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi across four factors: quality 61/100, value 52/100, growth 44/100, dividend 21/100. Its strongest factor is quality.
GENIL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.14B
- Revenue (TTM)
- $475.11M
- P/E
- 56.39
- EPS
- 0.22
- Dividend yield
- 0.40%
- Beta (5Y)
- -0.05
- 52-week high
- TL14.93
- 52-week low
- TL7.12
- Avg volume (3M)
- —
- Shares outstanding
- 4.50B
- Employees
- 682
- Next earnings
- —
About Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, trades, imports and exports of all kinds of human medicines and health products. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey.
- ISIN
- TREGENL00024
- Founded
- 1997
- Listed since
- Aug 6, 2021
- Exchange
- Borsa Istanbul (BIST)
- Currency
- TRY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.